LYR-220
Chronic Rhinosinusitis (CRS)
Not Specified (Pipeline)In development for patients with narrower sinonasal anatomy
Key Facts
Indication
Chronic Rhinosinusitis (CRS)
Phase
Not Specified (Pipeline)
Status
In development for patients with narrower sinonasal anatomy
Company
About Lyra Therapeutics
Lyra Therapeutics is focused on transforming the treatment paradigm for chronic rhinosinusitis (CRS), a debilitating inflammatory disease affecting 14 million people in the United States. The company leverages its proprietary drug-eluting nasal mesh technology to deliver sustained, localized therapy directly to the disease site, aiming to break the cycle of ineffective medical management. With its lead candidate, LYR-210, in Phase 3 development and a second candidate, LYR-220, in its pipeline, Lyra is positioned to address a large, underserved market. The company is publicly traded and led by an experienced team of drug developers.
View full company profileTherapeutic Areas
Other Chronic Rhinosinusitis (CRS) Drugs
| Drug | Company | Phase |
|---|---|---|
| LYR-210 | Lyra Therapeutics | Phase 3 |